BlueRock Therapeutics is a next-generation regenerative medicine company focused on breakthrough stem cell technology treatments of cardiovascular and neurodegenerative diseases. BlueRock Therapeutics has launched with the backing of a combined $225 million investment by Bayer and biotechnology investment firm Versant Ventures. BlueRock’s initial programs will focus on induced pluripotent stem cell (iPSC)-derived therapeutics to expand their technology pipeline.